Clinical trials: Liraglutide
Pouchitis, Irritable Pouch Syndrome
Efficacy of Liraglutide Therapy in Patients With IPAA
Patients with an ileal pouch-anal anastomosis(IPAA; pouch) due to refractory inflammatory bowel disease and increased bowel frequency in the absence of significant pouch inflammation will be randomized to liraglutide or placebo…
- Trial name
- NCT04763564
- Testing
- Liraglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of North Carolina, Chapel Hill
Insulin Resistance
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
- Trial name
- NCT02403284
- Testing
- Liraglutide, Sugar Pill
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Phoenix VA Health Care System
Diabetes Mellitus, Type 1
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Type 1 diabetes is an autoimmune disease characterized by destruction of pancreatic beta-cells, resulting in absolute deficiency of insulin. Presently there is no known cure.
- Trial name
- NCT03182426
- Testing
- Plerixafor, Alemtuzumab, Anakinra
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Alberta
Obesity, Childhood, Neural Development
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
To study the effects of liraglutide on neural responses to high fructose corn syrup (HFCS) in individuals with obesity.
- Trial name
- NCT03500484
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-alcoholic Fatty Liver Disease, Obesity
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).
- Trial name
- NCT06501326
- Testing
- Liraglutide, Orlistat
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Affiliated Hospital of Nantong University
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
3mg Liraglutide for Overweight or Obesity
In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and…
- Conditions
- Overweight, Obesity, Infertility, Female
- Trial name
- NCT03885297
- Testing
- Saxenda, Lifestyle modification, Metabolomics
- Where
- United Kingdom
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Healthy
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the pharmacokinetics of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared with Xultophy®.
- Trial name
- NCT06449703
- Testing
- insulin degludec/liraglutide, Xultophy®
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Obesity, HIV Infections
LIROH - Liraglutide for Obesity in HIV
The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined…
- Trial name
- LIROH (NCT06438146)
- Testing
- Liraglutide
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy
The purpose of the study is to collect information on how Xultophy® works in patients like them with type 2 diabetes. Participants will get Xultophy® as prescribed to them by the study doctor.
- Trial name
- NCT04666987
- Testing
- Insulin degludec and liraglutide (IDegLira)
- Where
- 28 sites in Italy
- Volunteers
- 359 people
- Sponsor
- Novo Nordisk A/S
Parkinson Disease
Safety and Efficacy of Liraglutide in Parkinson's Disease
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
- Trial name
- NCT02953665
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Cedars-Sinai Medical Center
Brain Death
The Use of Liraglutide in Brain Death
There is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood.
- Trial name
- NCT03672812
- Testing
- Liraglutide
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2.
- Trial name
- 1974 (NCT02777073)
- Testing
- Victoza, Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University at Buffalo
Type 1 Diabetes
Obesity Treatment to Improve Diabetes
As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal…
- Trial name
- OTID (NCT05390307)
- Testing
- Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.
- Trial name
- NCT01509742
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in…
- Trial name
- NCT02518945
- Testing
- Dapagliflozin, Insulin, Liraglutide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University at Buffalo
Type 1 Diabetes
Liraglutide in Type 1 Diabetes
The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes.
- Trial name
- 1966 (NCT01722240)
- Testing
- Liraglutide 1.8mg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Panhypopituitarism, Craniopharyngioma
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
GLP-1 analogs are used as agents in the existing treatment of obesity. However, there are lack of previous reports on the effectiveness and role of GLP-1 analogs in the development of obesity traits in patients with functionally…
- Conditions
- Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity
- Trial name
- NCT06217848
- Testing
- Saxenda
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital